جدول الترويج Acrivon Therapeutics, Inc.
الجدول الزمني المتقدم
رسم بياني بسيط
عن الشركة Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. مزيد من التفاصيلIPO date | 2022-11-15 |
---|---|
ISIN | US0048901096 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Сайт | https://www.acrivon.com |
Цена ао | 2.61 |
تغير السعر يوميا: | -11.11% (2.52) |
---|---|
تغير السعر في الأسبوع: | -58.21% (5.36) |
تغير السعر شهريا: | -57.82% (5.31) |
تغير السعر خلال 3 أشهر: | -62.16% (5.92) |
تغير السعر على مدى ستة أشهر: | -68% (7) |
تغير السعر سنويا: | -68.67% (7.15) |
تغير الأسعار منذ بداية العام: | -58.6% (5.41) |
|
الاستهانة
|
كفاءة
|
|||||||||||||||||||||||||||||||||||||
توزيعات الأرباح
|
واجب
|
دافع النمو
|
المؤسسات | مقدار | يشارك, % |
---|---|---|
RA Capital Management, L.P. | 4810508 | 21.25 |
Perceptive Advisors LLC | 3007858 | 13.29 |
Sands Capital Ventures, LLC | 1652605 | 7.3 |
Citadel Advisors Llc | 1649659 | 7.29 |
Wellington Management Group, LLP | 888130 | 3.92 |
Marshall Wace LLP | 597469 | 2.64 |
Blackrock Inc. | 565832 | 2.5 |
Vanguard Group Inc | 475977 | 2.1 |
NEA Management Company, LLC | 430252 | 1.9 |
Federated Hermes, Inc. | 226375 | 1 |
ETF | يشارك, % | الربحية لهذا العام, % | توزيعات الأرباح, % |
---|---|---|---|
Range Cancer Therapeutics ETF | 2.03779 | 47.24 | 0.11955 |
iShares Micro-Cap ETF | 0.02284 | 17.09 | 1.54048 |
Avantis U.S Small Cap Equity ETF | 0.00853 | 27.77 | 1.68271 |
![]() |
0.00415 | 17.47 | 1.51433 |
![]() |
0.0019 | 89.82 | 1.47873 |
ProShares Hedge Replication ETF | 0.00053 | 5.92 | 1.47892 |
![]() |
0.00053 | 24.86 | 1.43354 |
Vanguard Russell 2000 ETF | 0 | 17.16 | 1.48801 |
Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
0.23 | 31.02 | 1.35 |
مشرف | مسمى وظيفي | قسط | سنة الميلاد |
---|---|---|---|
Dr. Peter Blume-Jensen M.D., Ph.D. | Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer | 977.7k | 1963 (62 سنة) |
Ms. Kristina Masson M.B.A., Ph.D. | Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director | 739.78k | 1981 (44 سنة) |
Mr. Rasmus Holm-Jorgensen | Chief Financial Officer | 1M | 1972 (53 سنة) |
Dr. Eric J. Devroe Ph.D. | Chief Operating Officer | 614.78k | 1979 (46 سنين) |
Ms. Katharine Peterson CPA | Vice President of Finance & Accounting | N/A | |
Dr. Adam D. Levy M.B.A., Ph.D. | Senior VP and Head of Investor Relations & Corporate Affairs | N/A | |
Mr. Bruce Close | Vice President of Quality & Compliance | N/A | |
Ms. Mary-Alice Miller J.D. | Chief Legal Officer | 587.11k | 1974 (51 سنة) |
Ms. Parvin Miah | VP & Head of Human Resources | N/A | |
Dr. Erick Gamelin M.D., Ph.D. | Chief Development Officer | 480.72k | 1958 (67 سنين) |
عنوان: United States, Watertown. MA, 480 Arsenal Way - مفتوحة في خرائط جوجل, فتح خرائط ياندكس
موقع إلكتروني: https://www.acrivon.com
موقع إلكتروني: https://www.acrivon.com